Citations (79)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
HongJia Zhang, ZeLi Han, Yue Li, JiaHua Lin & YiHui Zou. (2023) Relationship between congenital malformation of the outer ear and hearing. Acta Oto-Laryngologica 143:sup1, pages S45-S48.
Read now
Read now
Serdar Celik, Tekincan Aktas, Ozde Gokbayrak, Aylin Erol, Kutsal Yorukoglu, Batuhan Yilmaz, Hilmi Sari, Zekiye Altun, Mehmet Ugur Mungan, Ilhan Celebi, Guven Aslan & Safiye Aktas. (2023) Genomic Alterations of Signaling and DNA Damage Repair Pathways in Non-Muscle Invasive Bladder Cancer. Cancer Investigation 41:10, pages 848-857.
Read now
Read now
Veronika Hanusova, Petra Matouskova, Monika Manethova, Jiri Soukup, Stanislav John, Martin Zofka, Hana Vošmikova, Lukas Krbal & Emil Rudolf. (2023) Comparative Analysis of miRNA and EMT Markers in Metastatic Colorectal Cancer. Cancer Investigation 41:10, pages 837-847.
Read now
Read now
Amber Veldman, Annika van Oosbree, Madisyn Braun, Aarabhi Gurumoorthy, William C. Spanos & Steven Powell. (2023) Assessment of Swallowing Function in Patients with Head and Neck Squamous Cell Carcinoma in High vs. Low Dose Cisplatin. Cancer Investigation 41:10, pages 807-815.
Read now
Read now
Michael D. Barnett & Allyson M. Coldiron. (2023) Development of the Virtual Kitchen Protocol for Prospective Memory: a virtual reality-based measure of everyday prospective memory abilities. Journal of Clinical and Experimental Neuropsychology 45:6, pages 618-635.
Read now
Read now
Juan F Alvarado-Muñoz, Agustín Falco, Agatha R Morales, Noé C Sánchez, Giovanni Reynoso, Allan Barillas, Jairo Moreno, Kreilin López, Rogelio Prestol, Angela Cabreja & César Nuñez. (2021) Platinum Ineligibility in Squamous Cell Carcinoma of the Head and Neck: Consensus from Central America and the Caribbean. Future Oncology 17:15, pages 1963-1971.
Read now
Read now
Cecilie Holländer-Mieritz, Jørgen Johansen, Gry A. Taarnhøj, Christoffer Johansen, Ivan R. Vogelius, Claus A. Kristensen & Helle Pappot. (2020) Systematic use of patient reported outcome during radiotherapy for head and neck cancer: study protocol for the national DAHANCA 38 trial . Acta Oncologica 59:5, pages 603-607.
Read now
Read now
Jérôme Fayette, Yann Molin, Emilie Lavergne, Xavier Montbarbon, Séverine Racadot, Marc Poupart, Antoine Ramade, Philippe Zrounba, Philippe Ceruse & Pascal Pommier. (2015) Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma. Drug Design, Development and Therapy 9, pages 6203-6210.
Read now
Read now
Tobenna Nwizu & David J Adelstein. (2014) In squamous cell head and neck cancer: which platinum, how much and how often?. Expert Review of Anticancer Therapy 14:9, pages 1033-1039.
Read now
Read now
Articles from other publishers (70)
Anouk W. M. A. Schaeffers, Lot A. Devriese, Carla H. van Gils, Jan Willem Dankbaar, Jens Voortman, Jan Paul de Boer, Marije Slingerland, Mathijs P. Hendriks, Ernst J. Smid, Geert W. J. Frederix & Remco de Bree. (2023) Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol. PLOS ONE 18:11, pages e0294147.
Crossref
Crossref
Allen P Johnson, Nithish Kumar, Abin Sam Daniel, Kiran Pramod, Raushan Kumar Chaudhary, Uday Venkat Mateti, Vijith Shetty & Shivakumar Hiremath. (2023) Healthcare Scheme to Overcome Financial Burden Associated with Chemoradiation Therapy in Head and Neck Cancer Patients: A Retrospective Single Centre Study. Indian Journal of Otolaryngology and Head & Neck Surgery 75:2, pages 794-801.
Crossref
Crossref
Sataksi Chatterjee, Naomi Kiyota, Richa Vaish, Atul Sharma, Makoto Tahara, Vanita Noronha, Kumar Prabhash & Anil D'Cruz. (2023) Weekly versus 3‐weekly cisplatin along with radiotherapy for locoregionally advanced non‐nasopharyngeal head and neck cancers: Is the equipoise in literature addressed yet?. Head & Neck 45:6, pages 1594-1603.
Crossref
Crossref
Long Chen, Yi-Chang Li, Min Hu, Shi-Jie Zhao & Qiang-Wei Yang. (2022) Efficacy and safety of weekly versus triweekly cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma: A meta-analysis. Medicine 101:52, pages e31842.
Crossref
Crossref
Nithin Bhaskar Valuvil & Lokesh Vishwanath. (2022) Simultaneous Modulated Accelerated Radiotherapy (SMART) with Dysphagia Aspiration-Related Structures (DARS) Sparing: Do We Have a Role for Dose Condensation in Locally Advanced Head and Neck Cancer. Asian Journal of Oncology 08, pages 119-126.
Crossref
Crossref
Naomi Kiyota, Makoto Tahara, Junki Mizusawa, Takeshi Kodaira, Hirofumi Fujii, Tomoko Yamazaki, Hiroki Mitani, Shigemichi Iwae, Yasushi Fujimoto, Yusuke Onozawa, Nobuhiro Hanai, Takenori Ogawa, Hiroki Hara, Nobuya Monden, Eiji Shimura, Shujiro Minami, Takashi Fujii, Kaoru Tanaka, Akihiro Homma, Seiichi Yoshimoto, Nobuhiko Oridate, Koichi Omori, Tsutomu Ueda, Kenji Okami, Ichiro Ota, Kiyoto Shiga, Masashi Sugasawa, Takahiro Asakage, Yuki Saito, Shigeyuki Murono, Yasumasa Nishimura, Kenichi Nakamura & Ryuichi Hayashi. (2022) Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial. Journal of Clinical Oncology 40:18, pages 1980-1990.
Crossref
Crossref
Michael G. McCusker, Ranee Mehra, Sania Amr, Rodney J. Taylor, Kevin J. Cullen & Olga G. Goloubeva. (2021) Comparison of efficacy and toxicity of chemoradiation regimens for head and neck squamous cell carcinoma primary treatment. Head & Neck 44:3, pages 749-759.
Crossref
Crossref
Ahmad Ameri, Shokoufe Norouzi, Ainaz Sourati, Samira Azghandi, Kambiz Novin & Farzad Taghizadeh‐Hesary. (2021)
Randomized trial on acute toxicities of weekly vs three‐weekly
cisplatin‐based
chemoradiation in head and neck cancer
. Cancer Reports 5:1.
Crossref
Crossref
Adity Chakraborty, Abhinandan Bhattacharjee, Amlan Jyoti Nath, Shibashis Deb & Aakanksha Rathor. (2021) Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma. The Egyptian Journal of Otolaryngology 37:1.
Crossref
Crossref
Shruthi Venkateshulu & Kiran Kumar BR. (2021) A Study Comparing Acute Toxicities of Cetuximab and Cisplatin in Patients Undergoing Definitive Chemoradiation With Intensity-Modulated Radiotherapy for Locally Advanced Carcinoma Head and Neck. Cureus.
Crossref
Crossref
Maria Gebre-Medhin, Eva Brun, Per Engström, Hedda Haugen Cange, Lalle Hammarstedt-Nordenvall, Johan Reizenstein, Jan Nyman, Edvard Abel, Signe Friesland, Helena Sjödin, Henrik Carlsson, Karin Söderkvist, Marcus Thomasson, Björn Zackrisson & Per Nilsson. (2021) ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. Journal of Clinical Oncology 39:1, pages 38-47.
Crossref
Crossref
Mete Gundog, Hatice Basaran, Oktay Bozkurt & Celalettin Eroglu. (2020) A comparison of cisplatin cumulative dose and cisplatin schedule in patients treated with concurrent chemo-radiotherapy in nasopharyngeal carcinoma. Brazilian Journal of Otorhinolaryngology 86:6, pages 676-686.
Crossref
Crossref
Devale Tousif, Vinu Sarathy, Rajesh Kumar & Radheshyam Naik. (2020) Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3-Weekly Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology 10.
Crossref
Crossref
James E. Jackson, Nigel J. Anderson, Morikatsu Wada, Michal Schneider, Michael Poulsen, Maureen Rolfo, Maziar Fahandej, Hui Gan, Daryl Lim Joon & Vincent Khoo. (2020) Clinical and dosimetric risk stratification for patients at high-risk of feeding tube use during definitive IMRT for head and neck cancer. Technical Innovations & Patient Support in Radiation Oncology 14, pages 1-10.
Crossref
Crossref
Jessica L. Geiger & David J. Adelstein. (2020) Chemotherapy in the definitive management of oral cancers: Where do we stand today?. Oral Oncology 102, pages 104584.
Crossref
Crossref
Manar Hamed Arafa & Hebatallah Husseini Atteia. (2019) Protective Role of Epigallocatechin Gallate in a Rat Model of Cisplatin-Induced Cerebral Inflammation and Oxidative Damage: Impact of Modulating NF-κB and Nrf2. Neurotoxicity Research 37:2, pages 380-396.
Crossref
Crossref
Sandro V. Porceddu, Florian Scotté, Matti Aapro, Satu Salmio, Ana Castro, Vincent Launay-Vacher & Lisa Licitra. (2020) Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy. Frontiers in Oncology 9.
Crossref
Crossref
Masanobu Mizuta, Ken Iwanaga, Akira Yoshizawa, Shin-ichi Sato & Hisanobu Tamaki. (2020) Treatment outcome of hypopharyngeal cancer: A single institutional experience多様化してきた下咽頭癌治療戦略の後ろ向き検討. Toukeibu Gan 46:4, pages 328-333.
Crossref
Crossref
Seth Helfenstein, Oliver Riesterer, Urs R. Meier, Alexandros Papachristofilou, Benjamin Kasenda, Miklos Pless & Sacha I. Rothschild. (2019) 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck – a multicentre, retrospective analysis. Radiation Oncology 14:1.
Crossref
Crossref
Kailin Wang, Jun Dong, Shasha He, Xia Wang, Chang Jiang, Pili Hu, Jiangui Guo, Xiuyu Cai & Xicheng Wang. (2019) Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma. BMC Cancer 19:1.
Crossref
Crossref
Nigel J. Anderson, James E. Jackson, Morikatsu Wada, Michal Schneider, Michael Poulsen, Maureen Rolfo, Maziar Fahandej, Hui Gan & Vincent Khoo. (2019) The changing landscape of head and neck cancer radiotherapy patients: is high‐risk, prolonged feeding tube use indicative of on‐treatment weight loss?. Journal of Medical Radiation Sciences 66:4, pages 250-258.
Crossref
Crossref
James E. Jackson, Nigel J. Anderson, Maureen Rolfo, Morikatsu Wada, Michal Schneider, Michael Poulsen, Maziar Fahandej, Anna Huynh, Sze Ting Lee, Daryl Lim Joon & Vincent Khoo. (2018) 18F-FDG Metabolic Tumor Volume: Association with Short- and Long-Term Feeding Tube Use in Head and Neck IMRT. Dysphagia 34:3, pages 341-349.
Crossref
Crossref
Nigel J. Anderson, James E. Jackson, Jennifer G. Smith, Morikatsu Wada, Michal Schneider, Michael Poulsen, Maureen Rolfo, Maziar Fahandej, Hui Gan, Daryl Lim Joon & Vincent Khoo. (2018) Pretreatment risk stratification of feeding tube use in patients treated with intensity-modulated radiotherapy for head and neck cancer. Head & Neck 40:10, pages 2181-2192.
Crossref
Crossref
Sarthak Tandon, Munish Gairola, Parveen Ahlawat, Sheh Rawat, Archana Aggarwal, Kanika Sharma, Sandeep Tiwari, Ahmad M. Karimi, Vinayakumar Muttagi, Nishtha Sachdeva & Manindra Bhushan. (2018) Randomized controlled study comparing simultaneous modulated accelerated radiotherapy versus simultaneous integrated boost intensity modulated radiotherapy in the treatment of locally advanced head and neck cancer. Journal of the Egyptian National Cancer Institute 30:3, pages 107-115.
Crossref
Crossref
So Yeon Lee, Yoon Seok Choi, Ik-Chan Song, Sang Gon Park, Bhumsuk Keam, Young Jun Yang, Eun-Kee Song, Hyo Jin Lee, Sang-Hee Cho, Hyeok Shim, Keon Uk Park, Ki-Hyeong Lee, Deog-Yeon Jo, Ihn-Seong Jo & Hwan-Jung Yun. (2018) Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer. Medicine 97:21, pages e10778.
Crossref
Crossref
Vanita NoronhaAmit JoshiVijay Maruti PatilJaiprakash AgarwalSarbani Ghosh-LaskarAshwini BudrukkarVedang MurthyTejpal GuptaAnil K. D’CruzShripad BanavaliPrathamesh S. PaiPankaj ChaturvediDevendra ChaukarNikhil PandeArun ChandrasekharanVikas TalrejaDilip Harindran VallatholVijayalakshmi MathrudevAparna ManjrekarKamesh MaskeArati Sanjay BhelekarKavita NawaleSadhana KannanVikram GotaAtanu BhattacharjeeShubhada KaneShashikant L. JuvekarKumar Prabhash. (2018) Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. Journal of Clinical Oncology 36:11, pages 1064-1072.
Crossref
Crossref
Jacek Mackiewicz, Agnieszka Rybarczyk-Kasiuchnicz, Izabela Łasińska, Małgorzata Mazur-Roszak, Daria Świniuch, Michał Michalak, Joanna Kaźmierska, Adam Studniarek, Łukasz Krokowicz & Tomasz Bajon. (2017) The comparison of acute toxicity in 2 treatment courses. Medicine 96:51, pages e9151.
Crossref
Crossref
JC Kennetth Jacinto, Jayson Co, Michael Benedict Mejia & Eugenio Emmanuel Regala. (2017)
The evidence on effectiveness of weekly
vs
triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis
. The British Journal of Radiology 90:1079.
Crossref
Crossref
Muneyuki Masuda, Takahiro Wakasaki, Satoshi Toh, Yoshinori Uchida, Hidefumi Rikimaru, Naonobu Kunitake & Yuichiro Higaki. (2017) Utility of chemoradioselection for the optimization of treatment intensity in advanced hypopharyngeal and laryngeal carcinoma. Molecular and Clinical Oncology.
Crossref
Crossref
Petr Szturz, Kristien Wouters, Naomi Kiyota, Makoto Tahara, Kumar Prabhash, Vanita Noronha, Ana Castro, Lisa Licitra, David Adelstein & Jan B. Vermorken. (2017) Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. The Oncologist 22:9, pages 1056-1066.
Crossref
Crossref
Paolo Bossi, Maria Cossu Rocca, Renzo Corvò, Roberta Depenni, Vittorio Guardamagna, Franco Marinangeli, Francesco Miccichè & Fabio Trippa. (2017) The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity. Critical Reviews in Oncology/Hematology 116, pages 82-88.
Crossref
Crossref
Takumi Hasegawa, Souichi Yanamoto, Mitsunobu Otsuru, Shin-ichi Yamada, Tsutomu Minamikawa, Takashi Shigeta, Tomofumi Naruse, Takatsugu Suzuki, Masashi Sasaki, Yoshihide Ota, Masahiro Umeda & Takahide Komori. (2017) Retrospective study of treatment outcomes after postoperative chemoradiotherapy in Japanese oral squamous cell carcinoma patients with risk factors of recurrence. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 123:5, pages 524-530.
Crossref
Crossref
Cesar Augusto Perez, Xiaoyong Wu, Mark J. Amsbaugh, Rahul Gosain, Wederson M. Claudino, Mehran Yusuf, Teresa Roberts, Dharamvir Jain, Alfred Jenson, Sujita Khanal, Craig I. Silverman, Paul Tennant, Jeffrey M. Bumpous, Neal E. Dunlap, Shesh N. Rai & Rebecca A. Redman. (2017) High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck. Oral Oncology 67, pages 24-28.
Crossref
Crossref
Balasankar R, Nehru B & Syed Fayaz Ahmed. (2017) THE COMPARISON BETWEEN WEEKLY BLEOMYCIN WITH THREE-WEEKLY CISPLATIN AND 5-FU DELIVERED CONCURRENTLY WITH RADIOTHERAPY IN HEAD AND NECK CANCER. Journal of Evolution of Medical and Dental Sciences 6:22, pages 1772-1777.
Crossref
Crossref
Dirk Rades, Daniel Seidl, Stefan Janssen, Primoz Strojan, Katarina Karner, Amira Bajrovic, Samer G. Hakim, Barbara Wollenberg & Steven E. Schild. (2016) Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. European Archives of Oto-Rhino-Laryngology 274:2, pages 1021-1027.
Crossref
Crossref
Brammer Caroline, Yahya Sundus, Dawson Dawn, Glaister Carol & Merrick Susan. (2016)
Cost analysis of cetuximab (Erbitux) plus radiotherapy (ERT)
versus
concomitant cisplatin plus radiotherapy (CRT) within an NHS oncology unit (single institution): a pilot study
. The British Journal of Radiology 89:1068.
Crossref
Crossref
Dirk Rades, Daniel Seidl, Stefan Janssen, Amira Bajrovic, Katarina Karner, Primoz Strojan & Steven E Schild. (2016) Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers. BMC Cancer 16:1.
Crossref
Crossref
Jian Guan, Yue Zhang, Qinyang Li, Yaowei Zhang, Lu Li, Min Chen, Nanjie Xiao & Longhua Chen. (2016) A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC). Oncotarget 7:43, pages 70185-70193.
Crossref
Crossref
Stuart E. Samuels, Avraham Eisbruch, Jonathan J. Beitler, June Corry, Carol R. Bradford, Nabil F. Saba, Michiel W. M. van den Brekel, Robert Smee, Primož Strojan, Carlos Suárez, William M. Mendenhall, Robert P. Takes, Juan P. Rodrigo, Missak HaigentzJr.Jr., Alexander D. Rapidis, Alessandra Rinaldo & Alfio Ferlito. (2015) Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?. European Archives of Oto-Rhino-Laryngology 273:10, pages 2877-2894.
Crossref
Crossref
Jonathan J. Beitler, Harry Quon, Christopher U. Jones, Joseph K. Salama, Paul M. Busse, Jay S. Cooper, Shlomo A. Koyfman, John A. Ridge, Nabil F. Saba, Farzan Siddiqui, Richard V. Smith, Francis Worden, Min Yao & Sue S. Yom. (2016)
ACR Appropriateness Criteria
®
Locoregional therapy for resectable oropharyngeal squamous cell carcinomas
. Head & Neck 38:9, pages 1299-1309.
Crossref
Crossref
Dirk Rades, Daniel Seidl, Stefan Janssen, Amira Bajrovic, Samer G. Hakim, Barbara Wollenberg, Katarina Karner, Primoz Strojan & Steven E. Schild. (2016) Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20 mg/m 2 cisplatin on five days every four weeks an alternative to 100 mg/m 2 cisplatin every three weeks?. Oral Oncology 59, pages 67-72.
Crossref
Crossref
Sjoukje F. Oosting, Tom W.W. Chen, Shao H. Huang, Lisa Wang, John Waldron, Ralph Gilbert, David Goldstein, Gyorgy B. Halmos, Max J.H. Witjes, Jourik A. Gietema, Brian O’Sullivan, Johannes A. Langendijk, Lillian L. Siu & Aaron R. Hansen. (2016) A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer. Oral Oncology 59, pages 43-49.
Crossref
Crossref
Preety Negi, Pamela Alice Kingsley, Himanshu Srivastava & Surender Kumar Sharma. (2016) Three Weekly Versus Weekly Cisplatin as Radiosensitizer in Head and Neck Cancer: a Decision Dilemma. Asian Pacific Journal of Cancer Prevention 17:4, pages 1617-1623.
Crossref
Crossref
Chantal M. L. Driessen, Geert O. Janssens, Winette T. A. van der Graaf, Robert P. Takes, Thijs A. W. Merkx, Willem J. G. Melchers, Hans A. M. Kaanders & Carla M. L. van Herpen. (2016) Toxicity and efficacy of accelerated radiotherapy with concurrent weekly cisplatin for locally advanced head and neck carcinoma. Head & Neck 38:S1, pages E559-E565.
Crossref
Crossref
Primož Strojan, Jan B. Vermorken, Jonathan J. Beitler, Nabil F. Saba, Missak HaigentzJrJr, Paolo Bossi, Francis P. Worden, Johannes A. Langendijk, Avraham Eisbruch, William M. Mendenhall, Anne W. M. Lee, Louis B. Harrison, Carol R. Bradford, Robert Smee, Carl E. Silver, Alessandra Rinaldo & Alfio Ferlito. (2016) Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head & Neck 38:S1, pages E2151-E2158.
Crossref
Crossref
Stefano Maria MagriniMichela BuglioneRenzo CorvòLuigi PirtoliFabiola PaiarPietro PonticelliAlessia PetrucciAlmalina BacigalupoMonica CrocianiLuciana LastrucciStefania VecchioPierluigi BonomoNadia PasinettiLuca TriggianiRoberta CavagniniLoredana CostaSandro TonoliMarta MaddaloSalvatore Grisanti. (2016) Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. Journal of Clinical Oncology 34:5, pages 427-435.
Crossref
Crossref
Ji Yun Lee, Jong-Mu Sun, Dong Ryul Oh, Sung Hee Lim, Juna Goo, Se-Hoon Lee, Sung-Bae Kim, Keon Uk Park, Hoon-Kyo Kim, Dae Sik Hong, Jun Suk Kim, Seong-Geun Kim, Seong Yoon Yi, Hwan Jung Yun, Myung Soo Hyun, Hyo Jung Kim, Sin-Ho Jung, Keunchil Park, Yong Chan Ahn & Myung-Ju Ahn. (2016) Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). Radiotherapy and Oncology 118:2, pages 244-250.
Crossref
Crossref
James M. Melotek, Benjamin T. Cooper, Matthew Koshy, Joshua S. Silverman & Michael T. Spiotto. (2016) Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer. Journal of Otolaryngology - Head & Neck Surgery 45:1.
Crossref
Crossref
Aaro Haapaniemi, Petri Koivunen, Kauko Saarilahti, Ilpo Kinnunen, Jussi Laranne, Leena‐Maija Aaltonen, Mervi Närkiö, Paula Lindholm, Reidar Grénman, Antti Mäkitie & Timo Atula. (2015) Laryngeal cancer in Finland: A 5‐year follow‐up study of 366 patients. Head & Neck 38:1, pages 36-43.
Crossref
Crossref
Nourdine Hamdane, Chelsea Herdman, Jean-Clement Mars, Victor Stefanovsky, Michel G. Tremblay & Tom Moss. (2015) Depletion of the cisplatin targeted HMGB-box factor UBF selectively induces p53-independent apoptotic death in transformed cells. Oncotarget 6:29, pages 27519-27536.
Crossref
Crossref
Myoung Hee Kang, Jung Hun Kang, Haa-Na Song, Bae Kwon Jeong, Gyu Young Chai, Kimun Kang, Seung Hoon Woo, Jung Je Park & Jin Pyeong Kim. (2014) Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma. Cancer Research and Treatment 47:3, pages 441-447.
Crossref
Crossref
Junlin Yi, Xiaodong Huang, Li Gao, Jingwei Luo, Shiping Zhang, Kai Wang, Yuan Qu, Jianping Xiao & Guozhen Xu. (2014) Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma. Radiation Oncology 9:1.
Crossref
Crossref
Chang-Juan Tao, Li Lin, Guan-Qun Zhou, Ling-Long Tang, Lei Chen, Yan-Ping Mao, Mu-Sheng Zeng, Tie-Bang Kang, Wei-Hua Jia, Jian-Yong Shao, Hai-Qiang Mai, Ai-Hua Lin, Jun Ma & Ying Sun. (2014) Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma. PLoS ONE 9:10, pages e110765.
Crossref
Crossref
Sue S Yom & Joseph WeeSue S YomJoseph Wee. 2014. Nasopharyngeal Carcinoma: Management Strategies. Nasopharyngeal Carcinoma: Management Strategies
230
242
.
Nemer Osman, Yasir Y. Elamin, Shereen Rafee, Cathal O’Brien, Leo F. A. Stassen, Conrad Timon, John Kinsella, Sinead Brennan & Kenneth J. O’Byrne. (2013) Weekly cisplatin concurrently with radiotherapy in head and neck squamous cell cancer: a retrospective analysis of a tertiary institute experience. European Archives of Oto-Rhino-Laryngology 271:8, pages 2253-2259.
Crossref
Crossref
Kang-Hsing Fan, Chien-Yu Lin, Chung-Jan Kang, Li-Yu Lee, Shiang-Fu Huang, Chun-Ta Liao, I-How Chen, Shu-Hang Ng, Hung-Ming Wang & Joseph Tung-Chieh Chang. (2014) Postoperative Concomitant Chemoradiotherapy Improved Treatment Outcomes of Patients with Oral Cavity Cancer with Multiple-Node Metastases but No Other Major Risk Factors. PLoS ONE 9:2, pages e86922.
Crossref
Crossref
Amanda Jagdis, Janessa Laskin, Desiree Hao, John Hay, Jonn Wu & Cheryl Ho. (2014) Dose Delivery Analysis of Weekly Versus 3-Weekly Cisplatin Concurrent With Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC). American Journal of Clinical Oncology 37:1, pages 63-69.
Crossref
Crossref
Meredith Johnston, Linxin Guo, Michael Back, Alex Guminski, Adrian Lee, Catherine Hanna, David Veivers, Andrew Wignall & Thomas Eade. (2013) Intensity‐modulated radiotherapy using simultaneous‐integrated boost for definitive treatment of locally advanced mucosal head and neck cancer: Outcomes from a single‐institution series. Journal of Medical Imaging and Radiation Oncology 57:3, pages 356-363.
Crossref
Crossref
David J. Pinato, Janet Graham, Hani Gabra & Rohini Sharma. (2013) Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treatment Reviews 39:2, pages 153-160.
Crossref
Crossref
Din-Li Tsan, Chien-Yu Lin, Chung-Jan Kang, Shiang-Fu Huang, Kang-Hsing Fan, Chun-Ta Liao, I-How Chen, Li-Yu Lee, Hung-Ming Wang & Joseph Tung Chieh Chang. (2012) The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiation Oncology 7:1.
Crossref
Crossref
V. Espeli, E. Zucca, M. Ghielmini, O. Giannini, A. Salatino, F. Martucci & A. Richetti. (2012) Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer. Oral Oncology 48:3, pages 266-271.
Crossref
Crossref
Matthias G Hautmann, Matthias Hipp & Oliver Kölbl. (2011) Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment?. Radiation Oncology 6:1.
Crossref
Crossref
Harry Quon, Traci Leong, Robert Haselow, Bruce Leipzig, Jay Cooper & Arlene Forastiere. (2011) Phase III Study of Radiation Therapy With or Without Cis-Platinum in Patients With Unresectable Squamous or Undifferentiated Carcinoma of the Head and Neck: An Intergroup Trial of the Eastern Cooperative Oncology Group (E2382). International Journal of Radiation Oncology*Biology*Physics 81:3, pages 719-725.
Crossref
Crossref
Zulfiquer OTTY, Monika Buhrer SKINNER, Joshua DASS, Michael COLLINS, Jennifer MOOI, Kandeepan THURAISINGAM & Sabe SABESAN. (2011) Efficacy and tolerability of weekly low‐dose cisplatin concurrent with radiotherapy in head and neck cancer patients. Asia-Pacific Journal of Clinical Oncology 7:3, pages 287-292.
Crossref
Crossref
Gregory J. Kubicek, Bruce F. Kimler, Fen Wang, Eashwer K. Reddy, Douglas A. Girod & Steven K. Williamson. (2011) Chemotherapy in Head and Neck Cancer. American Journal of Clinical Oncology 34:4, pages 380-384.
Crossref
Crossref
A. Homma, N. Inamura, N. Oridate, S. Suzuki, H. Hatakeyama, T. Mizumachi, S. Kano, T. Sakashita, R. Onimaru, K. Yasuda, H. Shirato & S. Fukuda. (2011) Concomitant Weekly Cisplatin and Radiotherapy for Head and Neck Cancer. Japanese Journal of Clinical Oncology 41:8, pages 980-986.
Crossref
Crossref
T. Kuhnt, A. Sandner, T. Wendt, R. Engenhart-Cabillic, G. Lammering, M. Flentje, G. Grabenbauer, A. Schreiber, A. Pirnasch & J. Dunst. (2010) Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Annals of Oncology 21:11, pages 2284-2289.
Crossref
Crossref
Harry Quon, Sue S. Yom, Madhur Kumar Garg, Joshua Lawson, Mark W. McDonald, John A. Ridge, Nabil Saba, Joseph Salama, Richard Smith, Anamaria Reyna Yeung & Jonathan J. Beitler. (2010) ACR Appropriateness Criteria®: Local–Regional Therapy for Resectable Oropharyngeal Squamous Cell Carcinomas. Current Problems in Cancer 34:3, pages 175-192.
Crossref
Crossref
Tejpal Gupta, Jai Prakash Agarwal, Sarbani Ghosh-Laskar, Purvish M Parikh, Anil K D'Cruz & Ketayun A Dinshaw. (2009) Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience. Head & Neck Oncology 1:1.
Crossref
Crossref
Diana Steinmann, Bettina Cerny, Johann Hinrich Karstens & Michael Bremer. (2009) Chemoradiotherapy with Weekly Cisplatin 40 mg/m2 in 103 Head-and-Neck Cancer PatientsRadiochemotherapie mit wöchentlichen Cisplatingaben von 40 mg/m2 bei 103 Patienten mit Kopf-Hals-Tumoren. Kumulative Cisplatindosis und Überleben. Strahlentherapie und Onkologie 185:10, pages 682-688.
Crossref
Crossref